超10亿美元！688221，牵手国际巨头

Core Viewpoint - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two of its small interfering RNA (siRNA) products, marking a significant step in the company's international recognition and collaboration in the field of small nucleic acid drugs [1][4]. Financial Aspects - Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million, with potential milestone payments reaching up to $950 million, bringing the total deal value to over $1 billion [3]. - The company will also earn tiered royalties on the global net sales of the two products [3]. Product Development and Responsibilities - One of the candidate drugs has entered the Investigational New Drug (IND) application stage, while the other is in the preclinical stage [4]. - Frontier Biotech will be responsible for advancing one product's Phase I clinical trial in China and supporting the IND research for the other product, while GSK will lead the global clinical development, registration, and commercialization efforts [4]. Industry Trends - Small nucleic acid drugs are gaining attention due to their short development cycles, broad therapeutic applications, long-lasting effects, and high success rates, expanding from rare genetic diseases to chronic diseases like cardiovascular and metabolic disorders [5]. - Since 2026, there have been numerous developments in the small nucleic acid field, including significant partnerships and acquisitions by various companies, indicating a growing interest and investment in this area [6]. Clinical Progress in China - Several domestic companies have entered clinical stages, with products targeting various diseases such as hepatitis B, cardiovascular, and metabolic disorders [7]. - Notable advancements include AHB-137 completing Phase III clinical enrollment in China and multiple pipelines from other companies progressing to global Phase II clinical trials [7]. Future Outlook - As technology matures and large pharmaceutical companies continue to invest, the application of small nucleic acid drugs is expanding from rare diseases to common chronic conditions, indicating a broad industry outlook [8]. - The collaboration between Frontier Biotech and GSK not only showcases the company's technical capabilities but also adds a new chapter to the internationalization path of Chinese small nucleic acid drug enterprises [8].